To date, various reports suggest that APPs have a profound impact on cancer development and the body’s innate immune system, however a putative prognostic value of combined serum APPs in NSCLC patients treated with immune therapy has not been explored. The gene discussed is CTSB; the disease is non-small cell lung carcinoma.